Alzheimer’s Disease Drug Candidates, Potential Treatments and Pipeline Analysis

    9
    SHARE

    The research report Alzheimer’s Disease Pipeline Review, H2 2018 provides comprehensive information on the therapeutics under development for Alzheimer’s Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. “Alzheimer’s Disease pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Complete research report on H1 2019 pipeline review of Alzheimer’s Disease with market data tables and figures, spread across 1333 pages is available at https://www.marketinsightsreports.com/reports/0926874683/Alzheimer-s-Disease-Pipeline-Review-H2-2018

    Companies Involved in Therapeutics Development are AB Science SA
    AbbVie Inc
    AC Immune SA
    Accera Inc
    Actinogen Medical Ltd
    Acumen Pharmaceuticals Inc
    Addex Therapeutics Ltd
    Aequus Pharmaceuticals Inc
    Affichem SA
    AFFiRiS AG
    Alector LLC
    Allergan Plc
    Allgenesis Biotherapeutics Inc
    Allinky Biopharma SL
    ALSP Inc
    Alzhyme Pty Ltd
    Alzinova AB
    AlzProtect SAS
    Amarantus Bioscience Holdings Inc
    Amgen Inc
    Anavex Life Sciences Corp
    Annexon Inc
    Aphios Corp
    Apodemus AB
    Applied Research using OMIC Sciences SL
    Araclon Biotech SL
    Archer Pharmaceuticals Inc
    ArmaGen Inc
    Asceneuron SA
    AstraZeneca Plc
    Aucta Pharmaceuticals LLC
    Auritec Pharmaceuticals Inc
    Avanir Pharmaceuticals Inc
    Avineuro Pharmaceuticals Inc
    Axon Neuroscience SE
    Axovant Sciences Ltd
    Axsome Therapeutics Inc
    Axxam SpA
    AZTherapies Inc
    Bactevo Ltd
    Beactica AB
    Berg LLC
    BioArctic AB
    Biogen Inc
    Biohaven Pharmaceutical Holding Company Ltd
    BioHealthonomics Inc
    BioXcel Therapeutics Inc
    Boehringer Ingelheim GmbH
    Bolder Biotechnology Inc
    Boryung Pharmaceutical Co Ltd
    Bristol-Myers Squibb Co
    Bsim2
    Cantabio Pharmaceuticals Inc
    Cardax Inc
    Carna Biosciences Inc
    Celon Pharma SA
    CHA Bio & Diostech Co Ltd
    Clera Inc
    Cognition Therapeutics Inc
    Cognosci Inc
    CohBar Inc
    Corium International Inc
    Coronis NeuroSciences Ltd
    Cortice Biosciences Inc
    Cotinga Pharmaceuticals Inc
    Crossbeta Biosciences BV
    CTD Holdings Inc
    Cypralis Ltd
    Daewoong Co Ltd
    Daiichi Sankyo Co Ltd
    DanPET AB
    Daval International Ltd
    Denali Therapeutics Inc
    Diffusion Pharmaceuticals Inc
    Dongkook Pharmaceutical Co Ltd
    Eisai Co Ltd
    Eli Lilly and Co
    Endece LLC
    Epigen Biosciences Inc
    F. Hoffmann-La Roche Ltd
    GemVax & KAEL Co Ltd
    Genentech Inc
    Genervon Biopharmaceuticals LLC
    GeneScience Pharmaceuticals Co Ltd
    GlaxoSmithKline Plc
    GliaCure Inc
    Glialogix Inc
    Golden Biotechnology Corp
    Grifols SA
    H. Lundbeck AS
    Hemostemix Inc
    Heptares Therapeutics Ltd
    HitGen LTD
    ICB International Inc
    Ichor Medical Systems Inc
    Icure Pharmaceutical Inc
    ID Pharma Co Ltd
    Immungenetics AG
    Immunwork Inc
    Impel NeuroPharma Inc
    India Globalization Capital Inc
    Inflazome Ltd
    Instituto Biomar SA
    Insys Therapeutics Inc
    IntelGenx Corp
    Intellect Neurosciences Inc
    Intra-Cellular Therapies Inc
    Io Therapeutics Inc
    Ionis Pharmaceuticals Inc
    Ironwood Pharmaceuticals Inc
    Jeil Pharmaceutical Co Ltd
    Jiangsu Kanion Pharmaceutical Co Ltd
    Johnson & Johnson
    K-Stemcell Co Ltd
    Kadmon Corp LLC
    Karuna Pharmaceuticals Inc
    Kyowa Hakko Kirin Co Ltd
    Lead Discovery Center GmbH
    Les Laboratoires Servier SAS
    Lipopharma Therapeutics SL
    Living Cell Technologies Ltd
    Lupin Ltd
    M3 Biotechnology Inc
    ManRos Therapeutics
    MedDay SA
    Medesis Pharma SA
    MedImmune LLC
    MEDRx Co Ltd
    MEI Pharma Inc
    MeiraGTx Holdings Plc
    Merck & Co Inc
    MindImmune Therapeutics Inc
    Mitsubishi Tanabe Pharma Corp
    ModGene Pharma LLC
    Montisera Ltd
    NAL Pharmaceuticals Ltd
    Nanomerics Ltd
    NeoNeuro SAS
    Neuralstem Inc
    Neuraltus Pharmaceuticals Inc
    Neurim Pharmaceuticals Ltd
    Neuro Bio Ltd
    Neuro-Sys SAS
    Neurodyn Life Sciences Inc
    NeuroGeneration Inc
    NeuroGenetic Pharmaceuticals Inc
    NeuroNascent Inc
    NeurOp Inc
    Neuropore Therapies Inc
    NeuroScientific Biopharmaceuticals Pty Ltd
    Neurotez Inc
    New World Laboratories Inc
    NoNO Inc
    Novartis AG
    Nymox Pharmaceutical Corp
    Ono Pharmaceutical Co Ltd
    Oryzon Genomics SA
    Otsuka Holdings Co Ltd
    Ovensa Inc
    Oxstem Ltd
    P2D Inc
    Pain Therapeutics Inc
    Peptron Inc
    Pharmasum Therapeutics AS
    Pharnext SA
    Phoenix Biotechnology Inc
    Prevacus Inc
    Priavoid GmbH
    Probiodrug AG
    Progenra Inc
    ProMIS Neurosciences Inc
    Proteome Sciences Plc
    Prothena Corp Plc
    QR Pharma Inc
    Quimatryx SL
    Radius Health Inc
    Regenera Pharma Ltd
    reMYND NV
    Revalesio Corp
    Rodin Therapeutics Inc
    Rodos BioTarget GmbH
    Sage Therapeutics Inc
    Samjin Pharm Co Ltd
    Samumed LLC
    SanBio Inc
    Sangamo Therapeutics Inc
    Sanofi
    SBI Pharmaceuticals Co Ltd
    Sentinel Oncology Ltd
    Serometrix LLC
    Shionogi & Co Ltd
    Shire Plc
    Simcere Pharmaceutical Group
    Spherium Biomed SL
    Summit Therapeutics Plc
    Suven Life Sciences Ltd
    T3D Therapeutics Inc
    Takeda Pharmaceutical Co Ltd
    TechnoPhage SA
    Teikoku Pharma USA Inc
    Telocyte LLC
    Tetra Discovery Partners LLC
    Tonix Pharmaceuticals Holding Corp
    Toyama Chemical Co Ltd
    Treventis Corp
    UCB SA
    Varinel Inc
    Virobay Inc
    VLP Therapeutics LLC
    Voyager Therapeutics Inc
    vTv Therapeutics Inc
    Vybion Inc
    Xigen SA
    Zensun (Shanghai) Sci & Tech Co Ltd
    Zhejiang Hisun Pharmaceutical Co Ltd

    The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer’s Disease.Alzheimer’s Disease. The pipeline guide reviews pipeline therapeutics for Alzheimer’s Disease. The pipeline guide reviews pipeline therapeutics for Alzheimer’s Diseaseby companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Alzheimer’s Disease therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Alzheimer’s Diseasetherapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer’s Disease.

    If you want sample copy of the report feel free to reach us at https://www.marketinsightsreports.com/reports/0926874683/Alzheimer-s-Disease-Pipeline-Review-H2-2018/inquiry

    This research report will help you to:-

    • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

    • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

    • Find and recognize significant and varied types of therapeutics under development.

    • Classify potential new clients or partners in the target demographic.

    • Develop tactical initiatives by understanding the focus areas of leading companies.

    • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

    • Formulate corrective measures for pipeline projects by understanding pipeline depth and focus of Indication therapeutics.

    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

    • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

    Avail Discount on this report @ https://www.marketinsightsreports.com/reports/0926874683/Alzheimer-s-Disease-Pipeline-Review-H2-2018/discount

    About Us: – MarketInsightsReports provides syndicated Market research reports to industries, organizations or even individuals with an aim of helping them in their decision making process. MarketInsightsReports has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
    +1 (704) 266-3234 | mail to: Sales @Marketinsightsreports.com